Markets

Estrella Immunopharma Appoints Cynthia Pussinen CEO, Chairperson, Effective Oct. 25, Succeeding Cheng Liu

Oct 26, 2026 · 08:08 AM ET· updated 1h ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS® T-cell therapies for the treatment of cancer and

Why It Matters

Estrella Immunopharma got a new leader starting October 25th. When a company swaps its top boss, watch how the team moves forward with its medicine goals.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ESLA1.11

+0.13 (+12.69%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.